Diagnosis and Treatment of Pancreas Rejection

Current Transplantation Reports

Volumn 2, Issue 2, 2015, Pages 169-175

  Redfield, R R ^a   Kaufman, D B ^a   Odorico, J S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Diagnosis; Pancreas rejection; Treatment

Indexed keywords

EID: 84991029578     PISSN: None     EISSN: 21963029     Source Type: Journal    
DOI: 10.1007/s40472-015-0061-x     Document Type: Article

References (20)

1. Kandaswamy R, Stock PG, Skeans MA, Gustafson SK, Sleeman EF, Wainright JL, et al. OPTN/SRTR 2011 annual data report: pancreas. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;1(13 Suppl):47–72. DOI: 10.1111/ajt.12020
2. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol. 2013;9(9):555–62. DOI: 10.1038/nrendo.2013.138
3. Redfield RR, McCune KR, Sollinger HW, Odorico JS. Pancreas allograft antibody mediated rejection: current concepts and future therapies. Trends Transplan. 2014;In Press.Very indepth and uptodate review of AMR.
4. Klassen DK, Hoen-Saric EW, Weir MR, Papadimitriou JC, Drachenberg CB, Johnson L, et al. Isolated pancreas rejection in combined kidney pancreas tranplantation. Transplantation. 1996;61(6):974–7. DOI: 10.1097/00007890-199603270-00024
5. Allen RD, Wilson TG, Grierson JM, Greenberg ML, Earl MJ, Nankivell BJ, et al. Percutaneous biopsy of bladder-drained pancreas transplants. Transplantation. 1991;51(6):1213–6. DOI: 10.1097/00007890-199106000-00013
6. Klassen DK, Weir MR, Cangro CB, Bartlett ST, Papadimitriou JC, Drachenberg CB. Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience. Transplantation. 2002;73(4):553–5. DOI: 10.1097/00007890-200202270-00011
7. Laftavi MR, Gruessner AC, Bland BJ, Foshager M, Walsh JW, Sutherland DE, et al. Diagnosis of pancreas rejection: cystoscopic transduodenal versus percutaneous computed tomography scan-guided biopsy. Transplantation. 1998;65(4):528–32. DOI: 10.1097/00007890-199802270-00013
8. de Kort H, Roufosse C, Bajema IM, Drachenberg CB. Pancreas transplantation, antibodies and rejection: where do we stand? Curr Opin Organ Transplant. 2013;18(3):337–44. DOI: 10.1097/MOT.0b013e3283614a5c
9. Nakhleh RE, Benedetti E, Gruessner A, Troppmann C, Goswitz JJ, Sutherland DE, et al. Cystoscopic biopsies in pancreaticoduodenal transplantation. Are duodenal biopsies indicative of pancreas dysfunction? Transplantation. 1995;60(6):541–6. DOI: 10.1097/00007890-199509270-00004
10. Klassen DK, Weir MR, Schweitzer EJ, Bartlett ST. Isolated pancreas rejection in combined kidney-pancreas transplantation: results of percutaneous pancreas biopsy. Transplant Proc. 1995;27(1):1333–4.
11. Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA, et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant. 2008;8(6):1237–49. DOI: 10.1111/j.1600-6143.2008.02212.x
12. Nakhleh RE, Sutherland DE. Pancreas rejection. Significance of histopathologic findings with implications for classification of rejection. Am J Surg Pathol. 1992;16(11):1098–107. DOI: 10.1097/00000478-199211000-00009
13. Drachenberg CB, Papadimitriou JC, Klassen DK, Racusen LC, Hoehn-Saric EW, Weir MR, et al. Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system. Transplantation. 1997;63(11):1579–86. DOI: 10.1097/00007890-199706150-00007
14. Drachenberg CB, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant. 2011;11(9):1792–802. DOI: 10.1111/j.1600-6143.2011.03670.x
15. Niederhaus SV, Leverson GE, Lorentzen DF, Robillard DJ, Sollinger HW, Pirsch JD, et al. Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes. Am J Transplant. 2013;13(11):2945–55. In this work, the authors describe rejection after pancreas transplantation from a large center. AMR occurs at a measurable rate after pancreas transplantation, and the diagnosis should be actively sought. DOI: 10.1111/ajt.12443
16. Dong M, Parsaik AK, Kremers W, Sun A, Dean P, Prieto M, et al. Acute pancreas allograft rejection is associated with increased risk of graft failure in pancreas transplantation. Am J Transplant. 2013;13(4):1019–25. DOI: 10.1111/ajt.12167
17. Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol: JASN. 2012;23(12):2061–71. DOI: 10.1681/ASN.2012070664
18. Cantarovich D, De Amicis S, Akl A, Devys A, Vistoli F, Karam G, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant. 2011;11(12):2737–46. DOI: 10.1111/j.1600-6143.2011.03729.x
19. Mittal S, Page SL, Friend PJ, Sharples EJ, Fuggle SV. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant. 2014;14(7):1664–71. Study demonstrating the detrimental effects of DSA on pancreas allograft outcomes. DOI: 10.1111/ajt.12750
20. Todeschini M, Cortinovis M, Perico N, Poli F, Innocente A, Cavinato RA, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol. 2013;191(5):2818–28. DOI: 10.4049/jimmunol.1203261